Literature DB >> 21214589

Female gender is associated with a better outcome after cardiac resynchronization therapy.

Francisco Leyva1, Paul W X Foley, Shajil Chalil, Nick Irwin, Russell E A Smith.   

Abstract

BACKGROUND: Some studies have suggested that women respond differently to cardiac resynchronization therapy (CRT). We sought to determine whether female gender influences long-term clinical outcome, symptomatic response as well as echocardiographic response after CRT. METHODS AND
RESULTS: A total of 550 patients (age 70.4 ± 10.7 yrs [mean ± standard deviation]) were followed up for a maximum of 9.1 years (median: 36.2 months) after CRT-pacing (CRT-P) or CRT-defibrillation (CRT-D) device implantation. Outcome measure included mortality as well as unplanned hospitalizations for heart failure or major adverse cardiovascular events (MACE). Female gender predicted survival from cardiovascular death (hazard ratio [HR]: 0.52, P = 0.0051), death from any cause (HR: 0.52, P = 0.0022), the composite endpoints of cardiovascular death /heart failure hospitalizations (HR: 0.56, P = 0.0036) and death from any cause/hospitalizations for MACE (HR: 0.67, P = 0.0214). Female gender predicted death from pump failure (HR: 0.55, P = 0.0330) but not sudden cardiac death. Amongst the 322 patients with follow-up echocardiography, left ventricular (LV) reverse remodelling (≥ 15% reduction in LV end-systolic volume) was more pronounced in women (62% vs 44%, P = 0.0051). In multivariable Cox proportional hazards analyses, the association between female gender and cardiovascular survival was independent of age, LV ejection fraction, atrial rhythm, QRS duration, CRT device type, New York Heart Association (NYHA) class, and LV reverse remodelling (adjusted HR: 0.48, P = 0.0086). At one year, the symptomatic response rate (improvement by ≥ 1 NYHA classes or ≥ 25% increase in walking distance) was 78% for both women and men.
CONCLUSIONS: Female gender is independently associated with a lower mortality and morbidity after CRT. ©2010, The Authors. Journal compilation ©2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21214589     DOI: 10.1111/j.1540-8159.2010.02909.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  12 in total

Review 1.  Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management.

Authors:  Pow-Li Chia; David Foo
Journal:  Singapore Med J       Date:  2016-07       Impact factor: 1.858

Review 2.  Device Management in Heart Failure.

Authors:  Brett G Angel; Heath Saltzman; Luke S Kusmirek
Journal:  Curr Cardiol Rep       Date:  2017-09-25       Impact factor: 2.931

Review 3.  Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?

Authors:  Khang-Li Looi; Nigel Lever; Anthony Tang; Sharad Agarwal
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

4.  Sex Differences in Utilisation and Response to Implantable Device Therapy.

Authors:  Deepika Narasimha; Anne B Curtis
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-08

5.  Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy.

Authors:  Zhonglin Han; Zheng Chen; Rongfang Lan; Wencheng Di; Xiaohong Li; Hongsong Yu; Wenqing Ji; Xinlin Zhang; Biao Xu; Wei Xu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

Review 6.  The impact of gender difference on clinical and echocardiographic outcomes in patients with heart failure after cardiac resynchronization therapy: A systematic review and meta-analysis.

Authors:  Fa-Hui Yin; Chun-Lei Fan; Ya-Ya Guo; Hai Zhu; Zhi-Lu Wang
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

7.  Renal function and the long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation.

Authors:  Francisco Leyva; Abbasin Zegard; Robin Taylor; Paul W X Foley; Fraz Umar; Kiran Patel; Jonathan Panting; Charles J Ferro; Shajil Chalil; Howard Marshall; Tian Qiu
Journal:  Pacing Clin Electrophysiol       Date:  2019-04-03       Impact factor: 1.976

8.  Survival after cardiac resynchronization therapy: results from 50 084 implantations.

Authors:  Francisco Leyva; Abbasin Zegard; Osita Okafor; Joseph de Bono; David McNulty; Asif Ahmed; Howard Marshall; Daniel Ray; Tian Qiu
Journal:  Europace       Date:  2019-05-01       Impact factor: 5.214

9.  Sex-Specific Differences in Survival and Heart Failure Hospitalization After Cardiac Resynchronization Therapy With or Without Defibrillation.

Authors:  Francisco Leyva; Tian Qiu; Abbasin Zegard; David McNulty; Felicity Evison; Daniel Ray; Maurizio Gasparini
Journal:  J Am Heart Assoc       Date:  2019-11-13       Impact factor: 5.501

10.  Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy.

Authors:  Bruce L Wilkoff; David Birnie; Michael R Gold; Ahmad S Hersi; Sandra Jacobs; Bart Gerritse; Kengo Kusano; Christophe Leclercq; Wilfried Mullens; Gerasimos Filippatos
Journal:  ESC Heart Fail       Date:  2020-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.